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EDITORIAL
Nitric oxide, advanced glycation end products, and uremia
The progressive and irreversible modification of tissue bonyl compounds suggests a molecular basis for the in-
proteins with advanced glycation end products (AGE) hibitory effect of NO on AGE formation [3]. Indeed,
is part of the normal process of aging. Advanced glyca- previous studies from the same group have shown that:
tion is the result of a slow, nonenzymatic process—the (i) reactive carbonyl compounds that accumulate in the
Maillard reaction—that affects proteins with a low turn- uremic plasma (a situation best described as “carbonyl
over, such as matrix components [1]. Advanced glycation stress”) are AGE precursors; and (ii) a relative excess
is amplified in case of sustained hyperglycemia, such as of reactive oxygen species (“oxidative stress”) yields in-
in diabetes, and the increased AGE levels correlate with creased amount of reactive carbonyl compounds [2, 4].
the severity of diabetic complications. In some instances, When scavenging free oxygen radicals, NO might thus
the process is even more rapid, with an attendant alter- decrease the oxidative stress and, thereby, the amount
ation of a greater variety of proteins. This is the case of carbonyl AGE precursors.
in renal failure, where AGE accumulate irrespective of If the acellular model used by Asahi et al provides an
elevated blood glucose and play a significant role in dis- excellent opportunity to investigate the effects of NO
orders that include accelerated vascular disease, trans- on the generation of AGE, several questions should be
formation of b2 amyloid, or stimulation of inflammatory answered before extrapolating these findings to in vivo
responses [2]. These findings have generated a consider-
situations. For instance, it remains unknown whether the
able interest for the events mediating advanced glyca-
production of NO as a free radical in these experimentaltion, in the hope of providing new therapeutic ap-
conditions somehow reflects a physiological state. In thatproaches to uremic toxicity and atherosclerosis.
respect, the S-nitrosation of albumin in solution mightIn the present issue of Kidney International, Asahi et
generate reactive nitrosothiols, exactly like in mamma-al offer a new perspective in the regulation of AGE
lian plasma [7]. On the other hand, the antioxidant prop-production by linking it to the prevailing effect of nitric
erties of NO are known to be modulated by local condi-oxide (NO) [3]. Using a well-established in vitro system,
tions such as pH, or levels of peroxynitrite (a powerfulthese investigators monitored the generation of pentosi-
oxidant derived from the reaction of NO with superoxidedine (an AGE product taken as a surrogate marker for
anion) [5]. Furthermore, if NO inhibits AGE formationadvanced glycation) in the presence of bovine serum
by scavenging free oxygen radicals, other investigatorsalbumin incubated for three days with various precur-
have shown that AGE themselves are able to quenchsors. They show that the addition of two different types
NO activity [8].of NO donors significantly inhibits pentosidine genera-
Another question is to whether NO synthase iso-tion in this system. Experiments performed with NO
forms—the enzymes that synthesize NO from l-argi-scavengers, or with the NO donor molecule or its degra-
dation product, demonstrate that the inhibition results nine—might also be affected by advanced glycation. For
from NO itself. In addition, Asahi et al confirm that instance, AGE promote the liberation of inflammatory
incubation of uremic plasma yields enhanced pentosi- cytokines from macrophages [2], which might in turn
dine formation [4], a process that is significantly reduced promote the expression of inducible NO synthase (iNOS).
in the presence of a NO donor. Another interaction might occur in the peritoneum of
These findings have important implications because uremic patients, a tissue that is exposed to high levels
they demonstrate an interaction between NO and AGE of circulating AGE (because of carbonyl stress) but also
in uremic patients [5, 6], and they provide a link between to high glucose in case of peritoneal dialysis (PD). Thus,
local AGE formation, decreased NO production and long-term PD has been associated with a progressive
endothelial dysfunction in atherosclerosis [2, 5]. Further- accumulation of AGE in the peritoneal membrane, to-
more, the demonstration by Asahi et al that NO donors gether with vascular proliferation, up-regulation of endo-
can scavenge free oxygen radicals liberated during gly- thelial NO synthase (eNOS) expression and activity, and
coxidation reactions and suppress the formation of car- increased nitrotyrosine reactivity [9].
Finally, whereas AGE levels are undoubtedly elevated
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with low NO levels [5, 6] remains controversial. Indeed,Ó 2000 by the International Society of Nephrology
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